The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial
The DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index.
Abstract
The short-acting glucagon-like peptide 1 receptor agonist exenatide reduces postprandial glycemia, partly by slowing gastric emptying, although its impact on small intestinal function is unknown. In this study, 10 healthy subjects and 10 patients with type 2 diabetes received intravenous exenatide (7.5 μg) or saline (-30 to 240 min) in a double-blind randomized crossover design. Glucose (45 g), together with 5 g 3-O-methylglucose (3-OMG) and 20 MBq (99m)Tc-sulfur colloid (total volume 200 mL), was given intraduodenally (t = 0-60 min; 3 kcal/min). Duodenal motility and flow were measured using a combined manometry-impedance catheter and small intestinal transit using scintigraphy. In both groups, duodenal pressure waves and antegrade flow events were fewer, and transit was slower with exenatide, as were the areas under the curves for serum 3-OMG and blood glucose concentrations. Insulin concentrations were initially lower with exenatide than with saline and subsequently higher. Nausea was greater in both groups with exenatide, but suppression of small intestinal motility and flow was observed even in subjects with little or no nausea. The inhibition of small intestinal motor function represents a novel mechanism by which exenatide can attenuate postprandial glycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, the action of GLP-1 and GLP-1 RAs (especially short acting) on gastric and intestinal cells causes, respectively, the deceleration of gastric emptying [31] and the reduction in intestine motility [32], which both impact the absorption of nutrients.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [32]
Citations
Cites
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“5 mg) was within the usual clinical range and was infused in a regimen shown previously to achieve steady therapeutic plasma concentrations (14,15).”
Bland, J. M., & Altman, D. G. (1995) · BMJ · doi:10.1136/bmj.310.6977.446 · Cited by 1,034
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817 · cited 6×
“Exogenous GLP-1 has been reported to inhibit both fasting and postprandial duodenal motility in humans (5,6), but its impact on the flow of chyme and on small intestinal transit and glucose absorption have not previously been explored.”
InfluentialAbnormal intestinal motility in diabetics with the gastroparesis syndrome
CAMILLERI, M., & MALAGELADA, J. (1984) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1984.tb01206.x · Cited by 328 · cited 1×
“Motility indices (MIs) were calculated as ln[(sum of amplitudes 3 number of duodenal waves) + 1] (12).”
Parker, B. A., Sturm, K., MacIntosh, C. G., Feinle, C., Horowitz, M., & Chapman, I. M. (2004) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601768 · Cited by 322 · cited 1×
“Venous blood was sampled frequently for blood glucose, serum 3-OMG and insulin, and plasma C-peptide concentrations, and gastrointestinal sensations were assessed using 100-mm visual analog questionnaires (11).”
Self-citationFehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297 · cited 1×
“5 mg) was within the usual clinical range and was infused in a regimen shown previously to achieve steady therapeutic plasma concentrations (14,15).”
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261 · cited 1×
“The rate of gastric emptying is an established determinant of postprandial blood glucose (2), a principle illustrated by “short-acting” glucagonlike peptide 1 (GLP-1) receptor agonists, such as exenatide, where the capacity to slow gastric emptying predominates over the insulinotropic effect in the postprandial settin…”
Self-citationBonapace, E. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)01988-2 · Cited by 183 · cited 1×
“Subjects remained supine under a gamma camera (7,8).”
Hellström, P. M., Näslund, E., Edholm, T., Schmidt, P. T., Kristensen, J., Theodorsson, E., Holst, J. J., & Efendic, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.01079.x · Cited by 160 · cited 1×
“Exogenous GLP-1 has been reported to inhibit both fasting and postprandial duodenal motility in humans (5,6), but its impact on the flow of chyme and on small intestinal transit and glucose absorption have not previously been explored.”
Little, T. J., Doran, S., Meyer, J. H., Smout, A. J. P. M., O'Donovan, D. G., Wu, K.-L., Jones, K. L., Wishart, J., Rayner, C. K., Horowitz, M., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00099.2006 · Cited by 130 · cited 1×
“The inhibition of motility and flow that we observed with exenatide is likely to have reduced the length of small intestinal mucosa exposed to glucose (18), which is supported by our scintigraphic data, and to have diminished the thinning of the unstirred water layer, which occurs with flow of chyme (19); both phenome…”
Self-citation
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Self-citationNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2021.2002616 · Cited by 236
Roles of the Gut in Glucose Homeostasis
Holst, J. J., Gribble, F., Horowitz, M., & Rayner, C. K. (2016) · Diabetes Care · doi:10.2337/dc16-0351 · Cited by 205
“Moreover, small intestinal motility and the flow of luminal content are determinants of glucose absorption, and these are potential targets for pharmacological manipulation (37).”
Self-citationClinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
“Similar phenomena are evident with the use of exenatide (24), which has been shown to inhibit small intestinal motility and increase gastrointestinal transit time in individuals with and without T2D (84).”
Self-citationGastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00188-2 · Cited by 144
Self-citationParker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz047 · Cited by 123
Mechanisms controlling hormone secretion in human gut and its relevance to metabolism
Martin, A. M., Sun, E. W., & Keating, D. J. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0399 · Cited by 109
Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity
Jensterle, M., Ferjan, S., Ležaič, L., Sočan, A., Goričar, K., Zaletel, K., & Janez, A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14944 · Cited by 102
Halim, M. A., Degerblad, M., Sundbom, M., Karlbom, U., Holst, J. J., Webb, D.-L., & Hellström, P. M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02006 · Cited by 102
Jalleh, R. J., Jones, K. L., Rayner, C. K., Marathe, C. S., Wu, T., & Horowitz, M. (2022) · Diabetologia · doi:10.1007/s00125-022-05796-1 · Cited by 87
Self-citationHorowitz, M., Aroda, V. R., Han, J., Hardy, E., & Rayner, C. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12872 · Cited by 79
“satiety, slowing gastric emptying and inhibiting small intestinal motility.(2,3) Differences between individual GLP-1RAs have been observed regarding the type and frequency of gastrointestinal events,(1) which”
Self-citationmiR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function
Jo, S., Chen, J., Xu, G., Grayson, T. B., Thielen, L. A., & Shalev, A. (2018) · Diabetes · doi:10.2337/db17-0506 · Cited by 80
“miR-204 Expression Is Low or Absent in Stomach or Exocrine Pancreas and GLP1R Expression Remains Unaltered in Response to miR-204 Deletion in These Tissues GLP1R is highly expressed on pancreatic b-cells but also in the exocrine pancreas, stomach, small intestine, and brain (28,29), and inhibition of gastric and small…”
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
Diabetes-induced mechanophysiological changes in the small intestine and colon
Zhao, M., Liao, D., & Zhao, J. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.249 · Cited by 74
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Michałowska, J., Miller-Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 68
Central GLP-1 receptors: Novel molecular targets for cocaine use disorder
Hernandez, N. S., & Schmidt, H. D. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.03.026 · Cited by 63
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Self-citationGLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
Tharakan, G., Behary, P., Wewer Albrechtsen, N. J., Chahal, H., Kenkre, J., Miras, A. D., Ahmed, A. R., Holst, J. J., Bloom, S. R., & Tan, T. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0446 · Cited by 61
Role of the intestinal microbiota in contributing to weight disorders and associated comorbidities
Hul, M. V., Neyrinck, A. M., Everard, A., Abot, A., Bindels, L. B., Delzenne, N. M., Knauf, C., & Cani, P. D. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00045-23 · Cited by 71
“After feeding, increased duodenal contractions causing segmental waves correlate with enhanced glucose absorption (107) due to expanded surface area for exchange between the gut lumen and the intestinal epithelium (108).”
Llewellyn, D. C., Logan Ellis, H., Aylwin, S. J. B., Oštarijaš, E., Green, S., Sheridan, W., Chew, N. W. S., le Roux, C. W., Miras, A. D., Patel, A. G., et al. (2023) · Obesity · doi:10.1002/oby.23600 · Cited by 54
Rayner, C. K., Watson, L. E., Phillips, L. K., Lange, K., Bound, M. J., Grivell, J., Wu, T., Jones, K. L., Horowitz, M., Ferrannini, E., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0190 · Cited by 50
“previously shown with exenatide (33), but we did not evaluate small intestinal function in the current study.”
Self-citationRole of intestinal glucose absorption in glucose tolerance
Wu, T., Rayner, C. K., Jones, K. L., Xie, C., Marathe, C. S., & Horowitz, M. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.017 · Cited by 53
Self-citationCharpentier, J., Briand, F., Lelouvier, B., Servant, F., Azalbert, V., Puel, A., Christensen, J. E., Waget, A., Branchereau, M., Garret, C., et al. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01657-8 · Cited by 51
Camilleri, M., & Lupianez-Merly, C. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002519 · Cited by 41
Diabetes and the Small Intestine
Gotfried, J., Priest, S., & Schey, R. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0155-x · Cited by 50
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
“GLP-1 decreases motility throughout the GI tract, and constipation and diarrhea are thus commonly reported (222, 223, 236).”
Bayesian metamodeling of complex biological systems across varying representations
Raveh, B., Sun, L., White, K. L., Sanyal, T., Tempkin, J. O. B., Zheng, D., Bharath, K., Singla, J., Wang, C., Zhao, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2104559118 · Cited by 37
Manipulation of Post-Prandial Hyperglycaemia in Type 2 Diabetes: An Update for Practitioners
Shibib, L., Al-Qaisi, M., Guess, N. D., Miras, A. D., Greenwald, S. E., Pelling, M., & Ahmed, A. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s458894 · Cited by 48
Hypoglycaemia and gastric emptying
Marathe, C. S., Marathe, J. A., Rayner, C. K., Kar, P., Jones, K. L., & Horowitz, M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13570 · Cited by 32
“The GLP-1RAs, while initially developed for their insulinotropic/ glucagonostatic properties, are now recognized as having effects on gastric and small intestinal motility.(87) Proof-of-principle studies indicate that short-acting and long-acting GLP-1RAs differ in their effects on gastric emptying with prolonged use.”
Self-citationClinical Pharmacokinetics and Pharmacodynamics of Albiglutide
Brønden, A., Knop, F. K., & Christensen, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0499-8 · Cited by 33
Miller, A., Deane, A., Plummer, M., Cousins, C. E., Chapple, L., Horowitz, M., & Chapman, M. (2017) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)00742-1 · Cited by 17
Self-citationLangmach Wegeberg, A., Hansen, C. S., Farmer, A. D., Karmisholt, J. S., Drewes, A. M., Jakobsen, P. E., Brock, B., & Brock, C. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620925968 · Cited by 28
Gastrointestinal Motility Effects of GLP-1 Receptor Agonists
Bellavance, D. R., Chua, S. G., & Mashimo, H. L. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00995-3 · Cited by 33
Tong, Y., Huang, J., Chen, Y., Tu, M., & Wang, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1176206 · Cited by 27
Wu, T., Rayner, C. K., & Horowitz, M. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0164 · Cited by 24
Self-citationA systematic review of the use of GLP-1 receptor agonists in surgery
Ihnat, J. M. H., Baun, H. M. D., Carrillo, G. A., Dony, A., Mukherjee, T. J., & Ayyala, H. S. (2024) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2024.116119 · Cited by 24
Nestel, N., Hvass, J. D., Bahl, M. I., Hansen, L. H., Krych, Ł., Nielsen, D. S., Dragsted, L. O., & Roager, H. M. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2020.594850 · Cited by 23
Xie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
Trapanese, V., Dagostino, A., Natale, M. R., Giofrè, F., Vatalaro, C., Melina, M., Cosentino, F., Sergi, S., Imoletti, F., Spagnuolo, R., et al. (2025) · Life · doi:10.3390/life15060843 · Cited by 25
“This interaction is particularly significant in terms of their profound effects on both gastric emptying [133,134] and small intestinal transit [135].”
Odah, T., Vattikonda, A., Stark, M. E., Brahmbhatt, B. S., Lukens, F., Badurdeen, D., Hashash, J. G., & Farraye, F. A. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.07.014 · Cited by 18
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“Furthermore, the action of GLP-1 and GLP-1 RAs (especially short acting) on gastric and intestinal cells causes, respectively, the deceleration of gastric emptying [31] and the reduction in intestine motility [32], which both impact the absorption of nutrients.”
Jalleh, R. J., Umapathysivam, M. M., Plummer, M. P., Deane, A. M., Jones, K. L., & Horowitz, M. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09823-3 · Cited by 22
Self-citationFactors associated with successful weight loss after liraglutide treatment for obesity
Sannaa, W., Dilmaghani, S., BouSaba, J., Maselli, D. B., Atieh, J., Eckert, D. J., Taylor, A. L., Harmsen, W. S., Acosta, A. J., & Camilleri, M. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14880 · Cited by 35
Nerild, H. H., Brønden, A., Gether, I. M., Hellmann, P. H., Baekdal, M., Gillum, M. P., Svenningsen, J. S., Hartmann, B., Rathor, N., Angelene, H., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15017 · Cited by 17
Thazhath, S. S., Marathe, C. S., Wu, T., Chang, J., Khoo, J. J. C., Kuo, P., Checklin, H. L., Bound, M. J., Rigda, R. S., Horowitz, M., et al. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116666761 · Cited by 14
Self-citationMa, J., & Vella, A. V. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00324 · Cited by 14
Applications of peptide hormone ligands for the treatment of dumping and short bowel syndrome
Wauters, L. I., & Vanuytsel, T. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.09.005 · Cited by 13
Voronova, V., Zhudenkov, K., Penland, R. C., Boulton, D. W., Helmlinger, G., & Peskov, K. V. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13326 · Cited by 12
Oyebode, O. A., Zuma, L. K., Erukainure, O. L., Koorbanally, N. A., & Islam, M. S. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1861026 · Cited by 14
Rayner, C. K., Jones, K. L., Wu, T., & Horowitz, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12822 · Cited by 9
Self-citationSrikrishnaraj, A., Jeong, H., & Brubaker, P. L. (2021) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2307 · Cited by 9
Chen, Y., Xiao, Y., Lian, G., Yi, J., & Liu, X. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2278708 · Cited by 10
Guo, L., Zhang, B., Hou, J., & Zhou, Z. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00869-z · Cited by 8
Horowitz, M., Rayner, C. K., Marathe, C. S., Wu, T., Umapathysivam, M. M., & Jones, K. L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14473 · Cited by 7
Self-citationJalleh, R. J., Wu, T., Umapathysivam, M. M., Young, R. L., Jones, K. L., Marathe, C. S., Rayner, C. K., Plummer, M. P., & Horowitz, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00009.2025 · Cited by 6
Self-citationProposed treatment strategy for reactive hypoglycaemia
Younes, Y. R., Cron, N., Field, B. C. T., Nayyar, V., Clark, J., Zachariah, S., Lakshmipathy, K., Isuga, J., Maghsoodi, N., & Emmanuel, J. J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1332702 · Cited by 7
Al-Humadi, A. W., Al‐Najim, W., Bleiel, S. B., & le Roux, C. W. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07492-y · Cited by 7
Romaní‐Pérez, M., Bullich‐Vilarrubias, C., López‐Almela, I., & Sanz, Y. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300474 · Cited by 5
Patel, H., Giri, P., & Srinivas, N. R. (2016) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-016-0373-y · Cited by 5
Jiang, Y., Cui, S., Zhang, R., Zhao, X., Yao, L., Ouyang, R., Chen, W., Zhou, R., Zhao, X., Tang, Z., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01107-w · Cited by 5
Hirota, Y., Matsuda, T., Nakajima, S., Takabe, M., Hashimoto, N., Nakamura, T., Okada, Y., Sakaguchi, K., & Ogawa, W. (2018) · Endocrine · doi:10.1007/s12020-018-1808-9 · Cited by 4
Gut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 6
“In patients with T2DM, GLP-1 RAs have been shown to inhibit gastric emptying, thereby contributing to the blood-glucose-lowering properties of GLP-1 alongside insulin stimulation and suppression of glucagon secretion [19].”
The Impact of Cholecystectomy in Patients with Post-Bariatric Surgery Hypoglycemia
Sardão, D., Sousa, H. S., Peleteiro, B., Resende, F., Costa-Pinho, A., Preto, J. R., Lima-da-Costa, E., Freitas, P., & CRI-O Group (2024) · Obesity Surgery · doi:10.1007/s11695-024-07325-y · Cited by 3
Rose, B. D., Pezos, N., Choo, J. M., Wu, T., Rogers, G. B., Ivey, K. L., Rayner, C. K., & Young, R. L. (2024) · Nutrients · doi:10.3390/nu16213628 · Cited by 3
Self-citationDamianos, J., Fredrick, T. W., Jin, M. F., Ospina-Velasquez, L., & Wang, X. J. (2025) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161251353437 · Cited by 2
Voetmann, L. M., Rolin, B., Kirk, R. K., Knudsen, L. B., Merkestein, M., Ahnfelt‐Rønne, J., Kodal, A. L. B., Jessen, C., Ozen, A. I., Pyke, C., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70510 · Cited by 3
Putman, M. S., Hull-Meichle, R. L., Waters, S. A., Tuggle, K. L., Sommer, P., Conway, R., Borthwick, L. A., Knudsen, J. G., Dean, E. D., Stanley, S. A., et al. (2026) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2026.03.021 · Cited by 2
Nathani, P., Hamamah, S., Velji-Ibrahim, J., Patel, H. K., Nathani, R., Radadiya, D. K., Shandilya, A., Srinivasan, S., Desai, M., Repici, A., et al. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10112-7 · Cited by 3
“Nausea and vomiting are believed to be multifactorial, with direct central nervous system (CNS) effects of the medication in regulating satiety [18, 27, 28], delayed gastric emptying [17, 18], and alterations in small bowel transit [18, 29] playing a role.”
Glucagon-like peptide-1 drugs, gastrointestinal function and critical illness
Nadkarni, A., Deane, A. M., & Plummer, M. P. (2026) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001376 · Cited by 3
Jones, K. L., Marathe, C. S., Wu, T., Rayner, C. K., & Horowitz, M. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_27 · Cited by 1
Self-citationJacob, V. Y. P., Felber, J., Muller, N., Kloos, C., Müller, U. A., & Stallmach, A. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1163-7230 · Cited by 1
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Isseki nichō (one stone, two birds): a dual incretin receptor agonist for type 2 diabetes
Jalleh, R. J., Rayner, C. K., Jones, K. L., & Horowitz, M. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00193-0
Self-citationRayner, C. K., Jones, K. L., & Horowitz, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13911-6.00001-3
Self-citation刘, 莹. (2024) · Traditional Chinese Medicine · doi:10.12677/tcm.2024.134124
Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea
Ziemke, F., Belarj, S., Esguerra, J., Reyes, A., & Istfan, N. W. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100178
Malbert, C., Delarue, J., & Guéant, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.07.004 · Cited by 1
Tuttle, Z., & Niewiadomski, O. (2026) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.70131
Metadata
- Authors
- Thazhath, S. S., Marathe, C. S., Wu, T., Chang, J., Khoo, J., Kuo, P., Checklin, H. L., Bound, M. J., Rigda, R. S., Crouch, B., Jones, K. L., Horowitz, M., & Rayner, C. K.
- Affiliations
- Royal Adelaide Hospital (AU)
- Corresponding author
- Rayner, Christopher K.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-10-15
- Volume
- 65
- Issue
- 1
- Pages
- 269-275
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1772233715
- Cited by
- 83
- References
- 26
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 14 · 2023: 8 · 2022: 6 · 2021: 10 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 8 · 2016: 7 · 2015: 1
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- UniSA Research Outputs Repository (University of South Australia) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- National Health and Medical Research Council of Australia
- AstraZeneca Australia
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, GLP-1 receptor agonists, small intestine motility, duodenal flow, small intestinal transit, glucose absorption, postprandial blood glucose, type 2 diabetes, 3-O-methylglucose, 99mTc-sulfur colloid scintigraphy, nausea, insulin response
- MeSH terms
- Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Diabetes Mellitus, Type 2, Double-Blind Method, Duodenum, Female, Gastric Emptying, Gastrointestinal Motility, Gastrointestinal Transit, Glucose, Humans, Hypoglycemic Agents, Intestine, Small, Male, Middle Aged, Peptides, Venoms, Case-Control Studies, Cross-Over Studies, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.